DRUG CAUSING HAEMATOLOGICAL DISORDER

-

 DRUG CAUSING HAEMATOLOGICAL DISORDER

There were five major blood dyscrasias attributable to drugs which are aplastic anemia, agranulocytosis, megaloblastic anemia, hemolytic anemia, and thrombocytopenia. It is usually rare compared to other adverse effects induced by drugs; however they are important because it is associated with significant morbidity and mortality.

Direct toxicity or immune reactions are the two main mechanisms which involved in druginduced haematological disorders.

The recommended treatment for drug-induced haematological disorders is by removing the causative drug and symptomatic support of the patient. Besides that, frequent monitoring of laboratory values is also warranted.

The common drugs that can induce haematological :are

Drugs Associated with Apalastic Anaemia


Acetazolamide Aspirin Captopril Chloramphenicol Chloroquine Felbamate Interferon alfa Chlorothiazide Chlorpromazine Dapsone Lisinopril Lithium Nizatidine Pentoxifylline Quinidine Sulindac Ticlopidine



Drugs Associated with Agranulocytosis


Acetaminophen Acetazolamide Ampicillin Captopril Cefotaxime Cefuroxime Chloramphenicol Chlorpramazine Chlorpropramide Chlorpheniramine Clindamycin Clozapine Colchicine Doxepin Dapsone Desipramine Ethosuximide Flucystosine Gentamicin Griseofulvin Hydralazine Hydroxychloroquine Imipenem-cilastatin Imipramine Lamotrigine Levodopa Methazolamide Methyldopa Metronidazole Nafcillin NSAIDs Olanzapine Oxacillin Penicillamine Penicillin G Phenytoin Pyrimethamine Quinidine Quinine Rifampicin Streptomycin Terbinafine Ticarcilin Tolbutamide VancomycinPrimidone Procainamide Propylthiouracil


Drugs Associated with Hemolytic Anaemia


Acetaminophen Angiotensin-converting enzyme inhibitors β-Lactam antibiotics Cephalosporins Ciprofloxacin Clavulanate Erythromycin Hydrochlorothiazide Indinavir Interferon alfa Ketoconazole Lansoprazole Levodopa Levofloxacin Methyldopa Minocycline NSAIDs Omeprazole p-Aminosalicylic acid Phenazopyridine Probenecid Procainamide Quinidine Rifabutin Rifampin Streptomycin Sulbactam Sulfonamides Sulfonylureas Tacrolimus Tazobactam Teicoplanin Tolbutamide Tolmetin Triamterene



Drugs Associated with Oxidative Hemolytic Anaemia


Ascorbic acid Metformin Methylene blue Nalidixic acid Nitrofurantoin Phenazopyridine Primaquine Sulfacetamide Sulfamethoxazole Sulfanilamide 


Drugs Associated with Megaloblastic Anaemia


Azathioprine Chloramphenicol Colchicine Cotrimoxazole Cyclophosphamide Cytarabine 5-Fluorodeoxyuridine 5-Fluorouracil Hydroxyurea 6-Mercaptopurine Methotrexate Oral contraceptives p-Aminosalicylate Phenobarbital Phenytoin Primidone Pyrimethamine Sulfasalazine Tetracycline Vinblastine


Drugs Associated with Thrombocytopenia


Abciximab Acetaminophen Acyclovir Albendazole Aminoglutethimide Aminosalicylic acid Amiodarone Amphotericin B Ampicillin Aspirin Atorvastatin Captopril Chlorothiazide Chlorpromazine Chlorpropamide Cimetidine Ciprofloxacin Clarithromycin Clopidogrel Danazol Deferoxamine Diazepam Diazoxide Diclofenac Digoxin Ethambutol Felbamate Fluconazole Gold salts Haloperidol Heparin Hydrochlorothiazide Ibuprofen Indinavir Levamisole Linezolid Lithium Indomethacin Interferon alfa Isoniazid Isotretinoin Itraconazole Low-molecular-weight heparins Measles, mumps, and rubella vaccine Mesalamine Methyldopa Minoxidil Naproxen Nitroglycerin Octreotide Cloxacillin p-Aminosalicylic acid Penicillamine Ranitidine Recombinant hepatitis B vaccine Rifampicin Simvastatin Sirolimus Sulfasalazine Sulfonamides Sulindac Tamoxifen Trimethoprim Vancomycin Pentoxifylline Piperacillin Primidone Procainamide Pyrazinamide Quinine Quinidine


Reference

Dipiro, J.T., Talbert, R.L., Yee, G.C., matzke, G.R., Wells, B.G., & Posey, L.M. (2008). Pharmacotherapy: A Pathophysiologic Approach 7th ed., McGraw Hill.


Comments

Post a Comment

Popular posts from this blog

Tryptyr (acoltremon) – The New FDA-Approved Breakthrough for Chronic Dry Eye

-
Image
✅  What Is Tryptyr (acoltremon)? Tryptyr-acoltremon In May 2025, the U.S. Food and Drug Administration (FDA) approved Tryptyr , a new and innovative treatment for chronic dry eye disease . The active ingredient, acoltremon , works by stimulating the body’s natural tear production—making it the first drug of its kind to target the root cause of dry eyes instead of just relieving symptoms. Tryptyr belongs to a new class of therapies that activate estrogen receptors in the lacrimal glands to restore the eye's natural moisture. 🧠 Why Are People Searching for Tryptyr? Users searching for Tryptyr are typically: Suffering from persistent dry eye symptoms (burning, itching, irritation) Seeking long-term relief beyond artificial tears Interested in the latest FDA-approved treatments Looking for an alternative to Restasis or Xiidra 🔬 How Tryptyr Works: A New Approach to Dry Eye Treatment Unlike traditional eye drops, Tryptyr stimulates the lacrimal glands through...
Read more

vinorelbine - Navelbine uses _side effects

-
Image
   Vinorelbine vinorelbine(vine-oh-rel-been) Navelbine   Classification vinorelbine   Therapeutic : antineoplastics Pharmacologic : vinca alkaloids   Pregnancy Category D  Indications vinorelbine Inoperable non–small-cell cancer of the lung in ambulatory patients (alone or with cisplatin).  Action of vinorelbine Binds to a protein (tubulin) of cellular microtubules, where it interferes with microtubule assembly. Cell replication is stopped as a result (cell cycle–specific for M phase).  Therapeutic Effects of vinorelbine  Death of rapidly replicating cells, particularly malignant ones.  Pharmacokinetics vinorelbine   Absorption : IV administration results in complete bioavailability.   Distribution : Highly bound to platelets and lymphocytes.  Metabolism and Excretion : Mostlymetabolized by the liver. At least one metabolite is active. Large amounts eliminated in feces; 11% excreted unchanged by the kidneys.  ...
Read more

Keytruda (Pembrolizumab): Effective Cancer Immunotherapy Option

-
Image
  Keytruda (Pembrolizumab) Cancer treatment has witnessed a significant shift with the advent of immunotherapy , and Keytruda (Pembrolizumab) stands at the forefront of this revolution. Recent studies have shown that immunotherapy can improve survival rates in various types of cancer. Keytruda , a leading immunotherapy drug, has been instrumental in this progress, offering new hope to patients with advanced cancer. By harnessing the power of the immune system, Pembrolizumab has demonstrated its efficacy in treating a range of cancers. Key Takeaways Cancer immunotherapy has emerged as a vital treatment option. Keytruda (Pembrolizumab) is a leading drug in cancer immunotherapy . Immunotherapy treatment can significantly improve cancer survival rates. Pembrolizumab has shown efficacy across various cancer types . The role of immunotherapy in cancer treatment continues to expand. Understanding Keytruda - Pembrolizumab In the realm of cancer treatment , Pembrolizumab , or Keyt...
Read more